Drugs / IPN10200
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04752774 | Apr 2021 → Mar 2029 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04821089 | Apr 2021 → Aug 2026 overdue | — | Ipsen | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06937931 | Jun 2025 → Mar 2027 expected | cervical dystonia | Ipsen | Recruiting | No outcome recorded |
| Phase 2 | NCT06625060 | Oct 2024 → Oct 2027 expected | migraine disorder | Ipsen | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07427797 | Feb → Dec 2026 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 3 | NCT07435428 | Feb → Dec 2026 expected | — | Ipsen | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-22 | Ipsen | Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III ipsen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN10200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625060 ↗ |
| Route | Intramuscular | “Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb.” NCT04752774 ↗ |